Glück Conviction Score™ ⓘ
JAZZ
Jazz Pharmaceuticals plc
ⓘ
Eingeschränkte Aussagekraft — erst 61 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Neutral
Hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
56,8
87 neu, 223 erhöht, 856,9M $ netto
Aktivist
10,4
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 217.29 | +6.1 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 173.04 | +33.2 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 231.04 | EMA50: 219.00 | |
| MACD-Histogramm | Bärisch | 10 % | -1.743 | Bearisch | |
| RSI(14) | Neutral | 10 % | 52.2 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 35.6 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 28.8 | +DI: 19.7 / −DI: 19.3 | |
| Z-Score(60) | Neutral | 5 % | 0.93 | In Range | |
| 52W-Position | Bullisch | 5 % | 92.9 % | Hoch 240.06 / Tief 105.93 | |
| Bollinger(20,2σ) | Neutral | 5 % | 28.1 % | Upper 242.95 / Mid 234.34 / Lower 225.72 | |
| LinReg-Slope(60) | Bullisch | 10 % | +1.0886 | R²=0.89 / annualisiert +129.4 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1.200 | 231,83 | -278.196,00 | -32,1% | |
| 2026-06-01 | COZADD BRUCE C | Director | Open Market Sale | -6.000 | 235,12 | -1.410.720,00 | -163,0% | |
| 2026-05-28 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1.192 | 236,97 | -282.468,24 | -32,6% | |
| 2026-05-28 | Pearce Samantha | Officer, EVP, Chief Commercial Officer | Open Market Sale | -6.907 | 235,41 | -1.625.976,87 | -187,9% | |
| 2026-05-22 | Winningham Rick E | Director | Open Market Sale | -2.741 | 241,57 | -662.143,37 | -76,5% | |
| 2026-05-22 | McSharry Heather Ann | Director | Open Market Sale | -2.000 | 241,00 | -482.000,00 | -55,7% | |
| 2026-05-01 | COZADD BRUCE C | Director | Open Market Sale | -6.000 | 203,33 | -1.219.980,00 | -141,0% | |
| 2026-04-01 | COZADD BRUCE C | Director | Open Market Sale | -24 | 191,74 | -4.601,87 | -0,5% | |
| 2026-04-01 | COZADD BRUCE C | Director | Open Market Sale | -3.684 | 190,22 | -700.777,85 | -81,0% | |
| 2026-04-01 | COZADD BRUCE C | Director | Open Market Sale | -2.292 | 190,94 | -437.630,58 | -50,6% | |
| 2026-03-09 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1.287 | 182,94 | -235.443,78 | -27,2% | |
| 2026-03-03 | COZADD BRUCE C | Director | Open Market Sale | -2.608 | 186,73 | -487.002,27 | -56,3% | |
| 2026-03-03 | COZADD BRUCE C | Director | Open Market Sale | -3.159 | 186,09 | -587.843,46 | -67,9% | |
| 2026-03-03 | COZADD BRUCE C | Director | Open Market Sale | -233 | 187,84 | -43.767,75 | -5,1% | |
| 2026-02-27 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1.117 | 190,91 | -213.243,45 | -24,6% | |
| 2026-02-27 | RIEDEL NORBERT G | Director | Open Market Sale | -3.415 | 192,00 | -655.680,00 | -75,8% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -3.523 | 193,58 | -681.993,26 | -78,8% | |
| 2026-02-26 | Henderson Mary Elizabeth | Officer, SVP, Technical Operations | Open Market Sale | -5.343 | 194,49 | -1.039.134,42 | -120,1% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -197 | 193,60 | -38.138,85 | -4,4% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -549 | 190,80 | -104.747,17 | -12,1% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -875 | 192,07 | -168.056,96 | -19,4% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1.009 | 192,79 | -194.526,62 | -22,5% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1.061 | 190,00 | -201.593,71 | -23,3% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -1.784 | 191,88 | -342.311,96 | -39,6% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -2.916 | 189,81 | -553.490,92 | -64,0% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -11.529 | 191,65 | -2.209.480,97 | -255,3% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -15.555 | 190,28 | -2.959.806,96 | -342,0% | |
| 2026-02-26 | Patil Neena M | Officer, EVP & Chief Legal Officer | Open Market Sale | -16.602 | 192,53 | -3.196.334,91 | -369,4% | |
| 2026-02-26 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -1.253 | 194,11 | -243.222,21 | -28,1% | |
| 2025-12-09 | Henderson Mary Elizabeth | Officer, SVP, Technical Operations | Open Market Sale | -2.238 | 169,51 | -379.365,62 | -43,8% | |
| 2025-12-05 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -160 | 171,11 | -27.377,60 | -3,2% | |
| 2025-12-05 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -4.500 | 171,20 | -770.405,40 | -89,0% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -30.487 | 178,06 | -5.428.567,05 | -627,3% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -8.380 | 179,23 | -1.501.943,21 | -173,6% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -507 | 179,79 | -91.154,70 | -10,5% | |
| 2025-11-26 | COZADD BRUCE C | Director | Open Market Sale | -38.126 | 177,27 | -6.758.672,27 | -781,0% | |
| 2025-11-20 | McSharry Heather Ann | Director | Open Market Sale | -3.415 | 177,78 | -607.126,55 | -70,2% | |
| 2025-11-18 | Winningham Rick E | Director | Open Market Sale | -5.500 | 180,86 | -994.728,35 | -115,0% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -8.382 | 180,88 | -1.516.131,13 | -175,2% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -5.517 | 181,81 | -1.003.071,15 | -115,9% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -3.384 | 180,09 | -609.410,69 | -70,4% | |
| 2025-11-18 | COZADD BRUCE C | Director | Open Market Sale | -717 | 182,60 | -130.924,85 | -15,1% | |
| 2025-11-18 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -5.250 | 182,07 | -955.867,50 | -110,5% | |
| 2025-11-18 | Carr Patricia | Officer, SVP, Chief Accounting Officer | Open Market Sale | -69 | 181,66 | -12.534,54 | -1,4% | |
| 2025-11-17 | Iannone Robert | Officer, EVP, Global Head of R&D & CMO | Open Market Sale | -7.159 | 168,26 | -1.204.573,34 | -139,2% | |
| 2025-10-03 | COZADD BRUCE C | Director | Open Market Sale | -3.500 | 140,00 | -490.000,00 | -56,6% | |
| 2025-10-01 | COZADD BRUCE C | Director | Open Market Sale | -2.000 | 131,78 | -263.560,00 | -30,5% | |
| 2025-09-02 | COZADD BRUCE C | Director | Open Market Sale | -3.000 | 127,23 | -381.690,00 | -44,1% | |
| 2025-09-02 | COZADD BRUCE C | Director | Open Market Sale | -3.000 | 130,00 | -390.000,00 | -45,1% | |
| 2025-08-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -1.000 | 113,21 | -113.210,00 | -13,1% | |
| 2025-07-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 110,00 | -55.000,00 | -6,4% | |
| 2025-07-01 | COZADD BRUCE C | Director, Officer, Chairman & CEO | Open Market Sale | -500 | 105,26 | -52.630,00 | -6,1% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.591.700 | 5.451.241 | 140.459 | 1.057.110.973 | Aufgestockt | +2,6% | |
| VANGUARD GROUP INC | 5.917.142 | 0 | 5.917.142 | 1.005.914.140 | Neu | +100,0% | |
| Capital World Investors | 2.673.376 | 2.666.602 | 6.774 | 505.401.733 | Aufgestockt | +0,3% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.648.333 | 0 | 2.648.333 | 500.667.354 | Neu | +100,0% | |
| FMR LLC | 2.275.762 | 800.925 | 1.474.837 | 430.232.708 | Aufgestockt | +184,1% | |
| FRANKLIN RESOURCES INC | 1.958.940 | 1.818.911 | 140.029 | 370.337.696 | Aufgestockt | +7,7% | |
| DIMENSIONAL FUND ADVISORS LP | 1.895.215 | 2.623.303 | -728.088 | 358.264.016 | Reduziert | -27,8% | |
| STATE STREET CORP | 1.891.646 | 1.837.793 | 53.853 | 357.615.676 | Aufgestockt | +2,9% | |
| EcoR1 Capital, LLC | 1.706.469 | 1.706.469 | 0 | 322.607.964 | Unverändert | 0,0% | |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1.676.142 | 1.677.132 | -990 | 316.874.674 | Reduziert | -0,1% | |
| AMERIPRISE FINANCIAL INC | 1.608.476 | 1.521.090 | 87.386 | 304.082.388 | Aufgestockt | +5,7% | |
| CITADEL ADVISORS LLC | 1.343.944 | 404.320 | 939.624 | 254.072.613 | Aufgestockt | +232,4% | |
| AQR CAPITAL MANAGEMENT LLC | 1.338.458 | 877.267 | 461.191 | 249.863.354 | Aufgestockt | +52,6% | |
| MILLENNIUM MANAGEMENT LLC | 1.287.911 | 1.218.211 | 69.700 | 243.479.575 | Aufgestockt | +5,7% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.237.617 | 1.197.236 | 40.381 | 234.026.208 | Aufgestockt | +3,4% | |
| BANK OF AMERICA CORP /DE/ | 1.014.800 | 915.144 | 99.656 | 191.847.960 | Aufgestockt | +10,9% | |
| Swedbank AB | 992.108 | 1.102.974 | -110.866 | 187.558.018 | Reduziert | -10,1% | |
| JPMORGAN CHASE & CO | 1.044.642 | 0 | 1.044.642 | 177.589.245 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 885.201 | 706.047 | 179.154 | 167.347.248 | Aufgestockt | +25,4% | |
| RENAISSANCE TECHNOLOGIES LLC | 819.374 | 836.774 | -17.400 | 154.902.655 | Reduziert | -2,1% | |
| Holocene Advisors, LP | 733.905 | 589.735 | 144.170 | 138.744.740 | Aufgestockt | +24,4% | |
| MORGAN STANLEY | 698.738 | 639.179 | 59.559 | 132.096.707 | Aufgestockt | +9,3% | |
| Allianz Asset Management GmbH | 610.297 | 598.832 | 11.465 | 115.376.648 | Aufgestockt | +1,9% | |
| Sofinnova Investments, Inc. | 598.327 | 959.860 | -361.533 | 113.113.719 | Reduziert | -37,7% | |
| GMT CAPITAL CORP | 581.000 | 638.500 | -57.500 | 109.838.050 | Reduziert | -9,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 535.062 | 547.743 | -12.681 | 101.153.471 | Reduziert | -2,3% | |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 517.284 | 182.201 | 335.083 | 97.792.587 | Aufgestockt | +183,9% | |
| Pacer Advisors, Inc. | 503.013 | 647.084 | -144.071 | 95.094.608 | Reduziert | -22,3% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 548.000 | 0 | 548.000 | 93.160.000 | Neu | +100,0% | |
| Boston Trust Walden Corp | 488.661 | 393.911 | 94.750 | 92.381.362 | Aufgestockt | +24,1% | |
| NORTHERN TRUST CORP | 488.522 | 476.871 | 11.651 | 92.355.085 | Aufgestockt | +2,4% | |
| GOLDENTREE ASSET MANAGEMENT LP | 475.550 | 420.341 | 55.209 | 89.762.591 | Aufgestockt | +13,1% | |
| WELLINGTON MANAGEMENT GROUP LLP | 458.014 | 112.560 | 345.454 | 86.587.548 | Aufgestockt | +306,9% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 440.510 | 424.290 | 16.220 | 83.278.416 | Aufgestockt | +3,8% | |
| Polaris Capital Management, LLC | 415.366 | 432.466 | -17.100 | 78.524.942 | Reduziert | -4,0% | |
| Alyeska Investment Group, L.P. | 411.015 | 323.384 | 87.631 | 77.702.386 | Aufgestockt | +27,1% | |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 407.114 | 396.877 | 10.237 | 76.965.125 | Aufgestockt | +2,6% | |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 365.451 | 228.642 | 136.809 | 69.088.512 | Aufgestockt | +59,8% | |
| Point72 Asset Management, L.P. | 364.434 | 175.000 | 189.434 | 68.896.248 | Aufgestockt | +108,2% | |
| UBS Group AG | 357.203 | 472.952 | -115.749 | 67.529.227 | Reduziert | -24,5% | |
| SOUTH PLAINS FINANCIAL, INC. | 386 | 0 | 386 | 65.620.000 | Neu | +100,0% | |
| Nuveen, LLC | 346.148 | 381.937 | -35.789 | 65.439.280 | Reduziert | -9,4% | |
| AMERICAN CENTURY COMPANIES INC | 328.657 | 291.359 | 37.298 | 62.132.606 | Aufgestockt | +12,8% | |
| Assenagon Asset Management S.A. | 320.000 | 0 | 320.000 | 60.496.000 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 298.090 | 199.302 | 98.788 | 56.353.915 | Aufgestockt | +49,6% | |
| JANE STREET GROUP, LLC | 278.515 | 187.210 | 91.305 | 52.653.261 | Aufgestockt | +48,8% | |
| Iron Triangle Partners LP | 292.170 | 0 | 292.170 | 49.668.900 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 262.553 | 500.486 | -237.933 | 49.635.645 | Reduziert | -47,5% | |
| Vestal Point Capital, LP | 290.000 | 0 | 290.000 | 49.300.000 | Neu | +100,0% | |
| VICTORY CAPITAL MANAGEMENT INC | 256.598 | 249.678 | 6.920 | 48.509.852 | Aufgestockt | +2,8% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5.591.700 | 5.451.241 | +2,6% | 1.057.110.973 | 9,98 |
| Capital World Investors | 2.673.376 | 2.666.602 | +0,3% | 505.401.733 | 4,77 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.648.333 | 0 | +100,0% | 500.667.354 | 4,73 |
| FMR LLC | 2.275.762 | 800.925 | +184,1% | 430.232.708 | 4,06 |
| FRANKLIN RESOURCES INC | 1.958.940 | 1.818.911 | +7,7% | 370.337.696 | 3,50 |
| DIMENSIONAL FUND ADVISORS LP | 1.895.215 | 2.623.303 | -27,8% | 358.264.016 | 3,38 |
| STATE STREET CORP | 1.891.646 | 1.837.793 | +2,9% | 357.615.676 | 3,38 |
| EcoR1 Capital, LLC | 1.706.469 | 1.706.469 | 0,0% | 322.607.964 | 3,04 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1.676.142 | 1.677.132 | -0,1% | 316.874.674 | 2,99 |
| AMERIPRISE FINANCIAL INC | 1.608.476 | 1.521.090 | +5,7% | 304.082.388 | 2,87 |
| CITADEL ADVISORS LLC | 1.343.944 | 404.320 | +232,4% | 254.072.613 | 2,40 |
| AQR CAPITAL MANAGEMENT LLC | 1.338.458 | 877.267 | +52,6% | 249.863.354 | 2,36 |
| MILLENNIUM MANAGEMENT LLC | 1.287.911 | 1.218.211 | +5,7% | 243.479.575 | 2,30 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.237.617 | 1.197.236 | +3,4% | 234.026.208 | 2,21 |
| JPMORGAN CHASE & CO | 1.204.353 | 1.044.642 | +15,3% | 220.577.545 | 2,08 |
| BANK OF AMERICA CORP /DE/ | 1.014.800 | 915.144 | +10,9% | 191.847.960 | 1,81 |
| Swedbank AB | 992.108 | 1.102.974 | -10,1% | 187.558.018 | 1,77 |
| BNP Paribas Asset Management Holding S.A. | 885.201 | 706.047 | +25,4% | 167.347.248 | 1,58 |
| RENAISSANCE TECHNOLOGIES LLC | 819.374 | 836.774 | -2,1% | 154.902.655 | 1,46 |
| Holocene Advisors, LP | 733.905 | 589.735 | +24,4% | 138.744.740 | 1,31 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 571 | 66,8 | 11.839 |
| 31.12.2025 | ✓ | 567 | 65,8 | 10.416 |
| 30.09.2025 | ✓ | 503 | 65,3 | 7.968 |
| 30.06.2025 | ✓ | 498 | 62,9 | 6.090 |
| 31.03.2025 | ✓ | 544 | 62,6 | 7.060 |
| 31.12.2024 | ✓ | 493 | 60,4 | 6.616 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| SOUTH PLAINS FINANCIAL, INC. | 386 | 65.620.000 |
| PERCEPTIVE ADVISORS LLC | 170.000 | 28.900.000 |
| Engineers Gate Manager LP | 100.847 | 17.143.990 |
| BANK OF NOVA SCOTIA | 86.200 | 14.654.000 |
| Simplify Asset Management Inc. | 71.178 | 12.100.260 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 60.100 | 10.217.000 |
| ING GROEP NV | 52.200 | 8.874.000 |
| PFM Health Sciences, LP | 50.511 | 8.586.870 |
| ARDSLEY ADVISORY PARTNERS LP | 50.000 | 8.500.000 |
| KVP Capital Advisors, LP | 48.500 | 8.245.000 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| FRANKLIN RESOURCES INC | 1.818.911 | 1.129.995 | +164.0 % | 309.214.909 |
| MILLENNIUM MANAGEMENT LLC | 1.218.211 | 949.104 | +352.7 % | 207.095.870 |
| Qube Research & Technologies Ltd | 500.486 | 444.242 | +789.8 % | 85.082.620 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 548.000 | 395.000 | +258.2 % | 93.160.000 |
| Sofinnova Investments, Inc. | 959.860 | 371.032 | +63.0 % | 163.176.200 |
| Allianz Asset Management GmbH | 598.832 | 242.892 | +68.2 % | 101.801.440 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 228.642 | 197.072 | +624.2 % | 38.869.140 |
| Ikarian Capital, LLC | 330.367 | 181.867 | +122.5 % | 56.162.390 |
| AQR CAPITAL MANAGEMENT LLC | 877.267 | 178.326 | +25.5 % | 149.135.332 |
| Point72 Asset Management, L.P. | 175.000 | 163.145 | +1376.2 % | 29.750.000 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | 1.044.642 | -822.517 | -44.1 % | 177.589.245 |
| GOLDENTREE ASSET MANAGEMENT LP | 420.341 | -716.765 | -63.0 % | 71.337.490 |
| CITADEL ADVISORS LLC | 404.320 | -528.225 | -56.6 % | 68.734.400 |
| Perpetual Ltd | 154.650 | -447.997 | -74.3 % | 26.290.500 |
| BALYASNY ASSET MANAGEMENT L.P. | 48.108 | -385.031 | -88.9 % | 8.178.360 |
| AMERIPRISE FINANCIAL INC | 1.521.090 | -326.365 | -17.7 % | 258.585.300 |
| Schonfeld Strategic Advisors LLC | 139.217 | -297.226 | -68.1 % | 23.666.890 |
| Estuary Capital Management LP | 106.387 | -256.760 | -70.7 % | 18.085.790 |
| Caption Management, LLC | 10.747 | -245.453 | -95.8 % | 1.826.990 |
| Woodline Partners LP | 41.222 | -223.746 | -84.4 % | 7.007.740 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,04 % | 3.103.522 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,11 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 10,11 % | 6.363.748 | -0,15 pp | |
| 11.09.2023 | The Vanguard Group | Passiv (13G/A) | 10,26 % | 6.479.474 | +0,65 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,61 % | 6.050.625 | +0,59 pp | |
| 05.01.2023 | JPMORGAN CHASE & CO. | Passiv (13G/A) | 4,60 % | 2.924.604 | -0,60 pp | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 9,02 % | 5.544.701 | +0,26 pp | |
| 10.02.2022 | Renaissance Technologies LLC 26-0385758 | Passiv (13G/A) | 2,77 % | 1.700.509 | -2,79 pp | |
| 10.02.2022 | RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 | Passiv (13G/A) | 2,77 % | 1.700.509 | -2,79 pp | |
| 24.01.2022 | JPMORGAN CHASE & CO. | Passiv (13G) | 5,20 % | 3.248.156 | Neu |
Stammdaten
Jazz Pharmaceuticals plc, ein Biopharmaunternehmen, identifiziert, entwickelt und vermarktet Arzneimittel für verschiedene ungedeckte medizinische Bedürfnisse in den Vereinigten Staaten, Europa und international. Das Unternehmen verfügt über ein Portfolio von Produkten und Produktkandidaten mit Fokus auf die Bereiche Neurowissenschaften, einschließlich Schlafmedizin und Bewegungsstörungen; sowie Onkologie, einschließlich hämatologischer und solider Tumoren. Zu den führenden vermarkteten Produkten gehören Xyrem, eine orale Lösung zur Behandlung von Kataplexie und übermäßiger Tagesmüdigkeit (EDS) bei Narkolepsie-Patienten ab sieben Jahren; Sunosi zur Behandlung von EDS bei Patienten mit Narkolepsie und obstruktiver Schlafapnoe; Erwinaze zur Behandlung von akuter lymphoblastischer Leukämie; Defitelio zur Behandlung von erwachsenen und pädiatrischen Patienten mit hepatischer Venenverschlussstörung; Vyxeos Liposom zur Injektion, ein Produkt zur Behandlung von erwachsenen Patienten mit neu diagnostizierter therapiebezogener akuter myeloischer Leukämie; und Zepzelca zur Behandlung von erwachsenen Patienten mit metastasierendem kleinzelligem Lungenkrebs. Das Unternehmen bietet auch Xywav, einen Oxybat-Produktkandidaten, zur Behandlung von EDS und Kataplexie bei Narkolepsie und idiopathischer Hypersomnie; JZP-324, eine Oxybat-Formulierung mit niedrigem Natriumgehalt mit dem Potenzial, eine klinisch bedeutsame Option für Narkolepsie-Patienten zu bieten; JZP385, einen T-Typ-Kalziumkanal-Modulator, zur Behandlung von essentiellem Tremor; JZP458, eine rekombinante Erwinia-Asparaginase, zur Verwendung als Komponente eines Multi-Agenten-Chemotherapieschemas zur Behandlung von pädiatrischen und erwachsenen Patienten; und JZP150 zur Behandlung von posttraumatischen Belastungsstörungen. Das Unternehmen hat Lizenz- und Kooperationsvereinbarungen mit ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; und Redx Pharma plc. Jazz Pharmaceuticals plc wurde 2003 gegründet und hat seinen Sitz in Dublin, Irland.
Unternehmen & Branche
| Name | Jazz Pharmaceuticals plc |
|---|---|
| Ticker | JAZZ |
| CIK | 0001232524 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | G50871105 |
|---|---|
| ISIN | USG508711052 |
| Typ | Common Stock |
| Marktkapitalisierung | 14,48 Mrd. USD |
| Beta | 0,29 |
Bewertung
| KBV (P/B) | 3,35 vs. 1,98 (2021) ▲ |
|---|---|
| KUV (P/S) | 3,39 vs. 2,54 (2021) ▲ |
| FCF-Rendite | 9,0 % vs. 9,6 % (2021) ▼ |
| Buyback-Rendite | 0,9 % vs. 0,0 % (2021) ▲ |
Qualität & Bilanz
| Operative Marge | -10,1 % vs. 5,5 % (2021) ▼ |
|---|---|
| Nettomarge | -8,3 % vs. -10,7 % (2021) ▲ |
| ROIC | -3,7 % vs. -3,3 % (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 1,98 | 3,26 | 2,05 | 1,82 | 2,42 | |
| KUV (P/S) | 2,54 | 2,75 | 2,00 | 1,84 | 2,45 | |
| EV/EBITDA | 68,1 | – | 19,6 | 15,0 | – | |
| FCF-Rendite | 9,6 % | 12,3 % | 13,9 % | 18,2 % | 12,4 % | |
| Buyback-Rendite | 0,0 % | 0,0 % | 3,5 % | 4,2 % | 1,2 % | |
| Qualität & Bilanz | ||||||
| Operative Marge | 5,5 % | -1,8 % | 15,1 % | 17,6 % | -10,1 % | |
| Nettomarge | -10,7 % | -6,1 % | 10,8 % | 13,8 % | -8,3 % | |
| ROIC | -3,3 % | -2,5 % | 4,4 % | 5,5 % | -3,7 % | |
| Nettoverschuldung/EBITDA | 28,3 | – | 7,0 | 5,0 | – | |
| Zinsdeckungsgrad | 1,9 | -2,0 | 17,6 | – | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 1.068.900.000 | 293.100.000 | 4,43 | 11.859.600.000 | 4.532.300.000 |
| 2025-12-31 | 10-K | 4.267.586.000 | -356.148.000 | -5,84 | 11.659.340.000 | 4.318.584.000 |
| 2025-09-30 | 10-Q | 1.126.107.000 | 251.412.000 | 4,08 | 11.356.485.000 | 3.959.030.000 |
| 2025-06-30 | 10-Q | 1.045.712.000 | -718.470.000 | -11,74 | 10.944.141.000 | 3.706.359.000 |
| 2025-03-31 | 10-Q | 897.841.000 | -92.541.000 | -1,52 | 11.534.682.000 | 4.174.891.000 |
| 2024-12-31 | 10-K | 4.068.950.000 | 560.120.000 | 8,65 | 12.012.257.000 | 4.093.756.000 |
| 2024-09-30 | 10-Q | 1.054.969.000 | 215.055.000 | 3,42 | 12.255.716.000 | 4.171.067.000 |
| 2024-06-30 | 10-Q | 1.023.825.000 | 168.568.000 | 2,49 | 11.361.868.000 | 3.762.599.000 |
| 2024-03-31 | 10-Q | 901.983.000 | -14.618.000 | -0,23 | 11.327.075.000 | 3.696.461.000 |
| 2023-12-31 | 10-K | 3.834.204.000 | 414.832.000 | 6,10 | 11.393.359.000 | 3.736.997.000 |
| 2023-09-30 | 10-Q | 972.140.000 | 146.820.000 | 2,14 | 11.204.065.000 | 3.489.373.000 |
| 2023-06-30 | 10-Q | 957.317.000 | 104.438.000 | 1,52 | 11.260.540.000 | 3.525.675.000 |
| 2023-03-31 | 10-Q | 892.812.000 | 69.420.000 | 1,04 | 11.047.125.000 | 3.335.041.000 |
| 2022-12-31 | 10-K | 3.659.374.000 | -224.060.000 | -3,58 | 10.835.255.000 | 3.085.734.000 |
| 2022-09-30 | 10-Q | 940.652.000 | -19.648.000 | -0,31 | 10.384.667.000 | 2.745.194.000 |
| 2022-06-30 | 10-Q | 932.878.000 | 34.665.000 | 0,55 | 11.200.133.000 | 3.200.781.000 |
| 2022-03-31 | 10-Q | 813.721.000 | 1.647.000 | 0,03 | 11.768.917.000 | 3.608.487.000 |
| 2021-12-31 | 10-K | 3.094.238.000 | -329.668.000 | -5,52 | 12.298.639.000 | 3.965.191.000 |
| 2021-09-30 | 10-Q | 838.115.000 | -52.833.000 | -0,86 | 12.478.152.000 | 3.938.477.000 |
| 2021-06-30 | 10-Q | 751.811.000 | -363.316.000 | -6,11 | 13.212.993.000 | 4.131.490.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product And Services Product Sales Net Of Deductions | 4,0 Mrd. | 3,8 Mrd. | 3,7 Mrd. | 3,6 Mrd. | 3,1 Mrd. | 32,1 % | +5,3% | |
| Total Neuroscience | 2,9 Mrd. | 2,7 Mrd. | 2,7 Mrd. | 2,8 Mrd. | – | 22,9 % | +6,7% | |
| Xywav | 1,7 Mrd. | 1,5 Mrd. | 1,3 Mrd. | 958,4 Mio. | 535,3 Mio. | 13,2 % | +12,5% | |
| Total Oncology | 1,1 Mrd. | 1,1 Mrd. | 1,0 Mrd. | 873,8 Mio. | – | 9,0 % | +1,6% | |
| Epidiolex Epidyolex | 1,1 Mrd. | 972,4 Mio. | 845,5 Mio. | 736,4 Mio. | 463,6 Mio. | 8,4 % | +8,9% | |
| Rylaze Enrylaze | 402,9 Mio. | 410,8 Mio. | 394,2 Mio. | 281,7 Mio. | – | 3,2 % | -1,9% | |
| Zepzelca | 307,3 Mio. | 320,3 Mio. | 289,5 Mio. | 269,9 Mio. | 246,8 Mio. | 2,5 % | -4,1% | |
| Product And Services Royalties And Contract Revenue | 245,7 Mio. | 247,8 Mio. | 97,3 Mio. | 17,9 Mio. | 15,2 Mio. | 2,0 % | -0,8% | |
| High Sodium AGOxybate Product Royalty Revenue | 211,7 Mio. | 217,6 Mio. | 75,9 Mio. | – | – | 1,7 % | -2,7% | |
| Defitelio Defibrotide | 199,4 Mio. | 216,6 Mio. | 184,0 Mio. | 194,3 Mio. | 197,9 Mio. | 1,6 % | -7,9% | |
| Vyxeos | 146,7 Mio. | 162,6 Mio. | 147,5 Mio. | 128,0 Mio. | 134,1 Mio. | 1,2 % | -9,8% | |
| Xyrem | 146,0 Mio. | 233,8 Mio. | 569,7 Mio. | 1,0 Mrd. | 1,3 Mrd. | 1,2 % | -37,5% | |
| Modeyso | 48,0 Mio. | – | – | – | – | 0,4 % | Neu | |
| Other Royalties And Contract Revenue | 34,0 Mio. | 30,2 Mio. | 21,3 Mio. | 17,9 Mio. | – | 0,3 % | +12,6% | |
| Ziihera | 24,8 Mio. | 1,1 Mio. | – | – | – | 0,2 % | +2260,6% | |
| Sativex | 16,3 Mio. | 18,9 Mio. | 19,7 Mio. | 16,8 Mio. | 12,7 Mio. | 0,1 % | -13,8% | |
| Other Products | 14,2 Mio. | 11,5 Mio. | 13,8 Mio. | 6,6 Mio. | 9,8 Mio. | 0,1 % | +23,5% | |
| Sunosi | – | – | – | 28,8 Mio. | 57,9 Mio. | – | – | |
| Neuroscience | – | – | – | – | 2,3 Mrd. | – | – | |
| Total Oxybate | – | – | – | – | 1,8 Mrd. | – | – | |
| Oncology | – | – | – | – | 733,8 Mio. | – | – | |
| Rylaze | – | – | – | – | 85,6 Mio. | – | – | |
| Erwinaze And Erwinase | – | – | – | – | 69,4 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| US | 3,8 Mrd. | 3,7 Mrd. | 3,5 Mrd. | 3,4 Mrd. | 2,8 Mrd. | 89,8 % | +4,7% | |
| Europe | 341,1 Mio. | 312,7 Mio. | 269,2 Mio. | 239,6 Mio. | 230,2 Mio. | 8,0 % | +9,1% | |
| Other Countries | 94,9 Mio. | 96,1 Mio. | 75,0 Mio. | 49,4 Mio. | 43,8 Mio. | 2,2 % | -1,3% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 1,1 Mrd. USD | 4,43 |
| Q3 2025 | 30.09.2025 | 05.11.2025 | 1,1 Mrd. USD | 4,08 |
| Q2 2025 | 30.06.2025 | 05.11.2025 | 1,0 Mrd. USD | -11,74 |
| Q1 2025 | 31.03.2025 | 05.05.2026 | 897,8 Mio. USD | -1,52 |
| Q3 2024 | 30.09.2024 | 05.11.2025 | 1,1 Mrd. USD | 3,42 |
| Q2 2024 | 30.06.2024 | 05.11.2025 | 1,0 Mrd. USD | 2,49 |
| Q1 2024 | 31.03.2024 | 05.11.2025 | 902,0 Mio. USD | -0,23 |
| Q3 2023 | 30.09.2023 | 07.11.2024 | 972,1 Mio. USD | 2,14 |
| Q2 2023 | 30.06.2023 | 07.11.2024 | 957,3 Mio. USD | 1,52 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 24.04.2026 | 10-K/A | – | – | SEC » |
| 24.02.2026 | 10-K | 31.12.2025 | 55 Tage | SEC » |
| 05.11.2025 | 10-Q | 30.09.2025 | 36 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 07.05.2025 | 10-Q | 31.03.2025 | 37 Tage | SEC » |
| 25.04.2025 | 10-K/A | 31.12.2024 | 115 Tage | SEC » |
| 26.02.2025 | 10-K | 31.12.2024 | 57 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 02.05.2024 | 10-Q | 31.03.2024 | 32 Tage | SEC » |
| 26.04.2024 | 10-K/A | 31.12.2023 | 117 Tage | SEC » |
| 28.02.2024 | 10-K | 31.12.2023 | 59 Tage | SEC » |
| 08.11.2023 | 10-Q | 30.09.2023 | 39 Tage | SEC » |
| 09.08.2023 | 10-Q | 30.06.2023 | 40 Tage | SEC » |
| 10.05.2023 | 10-Q | 31.03.2023 | 40 Tage | SEC » |
| 01.05.2023 | 10-K/A | 31.12.2022 | 121 Tage | SEC » |
| 01.03.2023 | 10-K | 31.12.2022 | 60 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 03.08.2022 | 10-Q | 30.06.2022 | 34 Tage | SEC » |
| 04.05.2022 | 10-Q | 31.03.2022 | 34 Tage | SEC » |
| 02.05.2022 | 10-K/A | 31.12.2021 | 122 Tage | SEC » |
| 01.03.2022 | 10-K | 31.12.2021 | 60 Tage | SEC » |
| 09.11.2021 | 10-Q | 30.09.2021 | 40 Tage | SEC » |
| 03.08.2021 | 10-Q | 30.06.2021 | 34 Tage | SEC » |
| 04.05.2021 | 10-Q | 31.03.2021 | 34 Tage | SEC » |
| 23.04.2021 | 10-K/A | 31.12.2020 | 113 Tage | SEC » |
| 23.02.2021 | 10-K | 31.12.2020 | 54 Tage | SEC » |
| 02.11.2020 | 10-Q | 30.09.2020 | 33 Tage | SEC » |
| 04.08.2020 | 10-Q | 30.06.2020 | 35 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (29.05.2026)
HOCH Abgang Schlüsselpersonen (29.05.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 29.05.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 28.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors… |
| 05.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the… |
| 25.02.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-08 | 2.466 | 226,96 | 559.683 |
| 2026-05-06 | 19.376 | 212,26 | 4.112.750 |
| 2026-04-29 | 6 | 203,98 | 1.224 |
| 2026-04-20 | 6 | 203,42 | 1.221 |
| 2026-04-08 | 20 | 190,94 | 3.819 |
| 2026-04-07 | 335 | 186,85 | 62.595 |
| 2026-04-06 | 4 | 186,95 | 748 |
| 2026-03-31 | 4 | 183,15 | 733 |
| 2026-03-27 | 1.695 | 189,15 | 320.609 |
| 2026-03-23 | 594 | 180,62 | 107.288 |
| 2026-03-17 | 45 | 182,02 | 8.191 |
| 2026-03-11 | 51 | 185,93 | 9.482 |
| 2026-02-13 | 1.782 | 166,29 | 296.329 |
| 2026-02-05 | 4.788 | 165,72 | 793.467 |
| 2026-02-04 | 3.832 | 166,84 | 639.331 |
| 2026-01-27 | 4.791 | 166,35 | 796.983 |
| 2026-01-20 | 11.128 | 169,41 | 1.885.194 |
| 2026-01-16 | 7.175 | 171,16 | 1.228.073 |
| 2026-01-15 | 38 | 170,81 | 6.491 |
| 2026-01-05 | 413 | 173,15 | 71.511 |
| 2025-12-31 | 5 | 170,82 | 854 |
| 2025-12-26 | 83 | 170,80 | 14.176 |
| 2025-12-24 | 1.669 | 169,47 | 282.845 |
| 2025-12-23 | 358 | 169,67 | 60.742 |
| 2025-12-22 | 1.168 | 166,99 | 195.044 |
| 2025-12-18 | 211 | 164,92 | 34.798 |
| 2025-12-17 | 2.344 | 169,73 | 397.847 |